Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
Clinical Cancer Research.
Times cited: 82
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
JAMA - Journal of the American Medical Association.
Times cited: 323